Nektar Therapeutics (NKTR) Amortization of Goodwill (2023)

Nektar Therapeutics (NKTR) recorded quarterly Amortization of Goodwill of $76.5 million in Q1 2023.

Nektar Therapeutics (NKTR) Amortization of Goodwill (2023) Analysis & Trends

Nektar Therapeutics' Amortization of Goodwill history runs 1 years deep, the most recent figure standing at $76.5 million for Q1 2023.

In Q1 2023, Amortization of Goodwill changed N/A year-over-year to $76.5 million; the TTM figure through Dec 2023 stood at $76.5 million (changed N/A YoY), while the FY2023 annual figure was $76.5 million, changed N/A from the prior year.
Amortization of Goodwill was $76.5 million for Q1 2023 at Nektar Therapeutics.
In the past five years, Amortization of Goodwill ranged from a high of $76.5 million in Q1 2023 to a low of $76.5 million in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Nektar Therapeutics	1.51 Bn	939.55 Mn	3.16 Mn

Historic Data

Download Data

Date	Value
Mar 31, 2023	76.50 Mn
Mar 31, 2023	76.50 Mn